Protagonist Therapeutics, Inc. $PTGX Shares Sold by Great Lakes Advisors LLC

by · The Markets Daily

Great Lakes Advisors LLC decreased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 36.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,171 shares of the company’s stock after selling 50,220 shares during the quarter. Great Lakes Advisors LLC owned about 0.14% of Protagonist Therapeutics worth $5,924,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Guggenheim Capital LLC increased its stake in Protagonist Therapeutics by 1.6% in the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after purchasing an additional 303 shares during the period. Bessemer Group Inc. increased its position in Protagonist Therapeutics by 171.0% in the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after acquiring an additional 318 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Protagonist Therapeutics by 16.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company’s stock valued at $132,000 after acquiring an additional 340 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Protagonist Therapeutics by 0.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock valued at $1,810,000 after acquiring an additional 348 shares during the last quarter. Finally, CWM LLC lifted its position in Protagonist Therapeutics by 201.5% during the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after acquiring an additional 407 shares during the period. 98.63% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PTGX shares. Johnson Rice set a $112.00 target price on Protagonist Therapeutics in a report on Monday, October 13th. Truist Financial boosted their price objective on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Barclays upped their price objective on shares of Protagonist Therapeutics from $88.00 to $108.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. JPMorgan Chase & Co. lifted their target price on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, BTIG Research reissued a “buy” rating and set a $82.00 price target on shares of Protagonist Therapeutics in a report on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Protagonist Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $86.77.

Read Our Latest Research Report on PTGX

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 13,151 shares of the company’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $82.42, for a total value of $1,083,905.42. Following the sale, the insider owned 84,115 shares of the company’s stock, valued at approximately $6,932,758.30. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Asif Ali sold 46,203 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total value of $3,840,855.39. Following the completion of the transaction, the chief financial officer owned 60,320 shares of the company’s stock, valued at approximately $5,014,401.60. This represents a 43.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 165,167 shares of company stock valued at $13,732,039 in the last ninety days. Corporate insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Stock Down 2.5%

Shares of NASDAQ PTGX opened at $79.73 on Friday. The stock has a market capitalization of $4.98 billion, a price-to-earnings ratio of 128.60 and a beta of 2.26. Protagonist Therapeutics, Inc. has a 52 week low of $33.70 and a 52 week high of $96.54. The firm has a 50-day moving average price of $86.33 and a 200 day moving average price of $72.53.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. The company had revenue of $4.71 million during the quarter, compared to analysts’ expectations of $5.41 million. Equities research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Protagonist Therapeutics Company Profile

(Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.

Further Reading